ArticleCellular and molecular life sciences : CMLS2026
Dual-specificity phosphatase 10 alleviates severe acute pancreatitis via the dephosphorylation of TAK1.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Severe acute pancreatitis (SAP) is a serious condition characterized by an intense systemic inflammatory response that can lead to persistent multiple organ failure and sepsis. Dual-specificity phosphatase 10 (DUSP10), has been implicated in immunity and inflammation; however, its involvement in SAP remains unclear. This study focuses on exploring the function and mechanism of DUSP10 in SAP. As a classical experimental model of SAP, L-arginine was used for in vitro and in vivo studies. A DUSP10 global knockout (KO) mice model and administration of adeno-associated virus with DUSP10 were used to further investigate the function of DUSP10 in SAP. Disulfiram and 5Z-7-ox, inhibitors of pyroptosis and TAK1, were applied to study the protective mechanism of DUSP10. We found downregulated expression of DUSP10 in in vitro and in vivo SAP models. Pancreatic damage was largely enhanced in DUSP10-/- mice and AR42J cells treated with shDUSP10, but was attenuated in mice and AR42J cells overexpressing DUSP10; the related lung and kidney damage, inflammatory response and oxidative stress paralleled these results. DUSP10 deficiency exacerbates pyroptosis during SAP, and inhibition of pyroptosis by DSF treatment protects against DUSP10 deficiency in aggravating SAP. Immunofluorescence and immunoprecipitation assays prove direct physical binding of DUSP10 to TAK1, and treatment with 5Z-7-ox reduced SAP severity in DUSP10-/- mice, showing that DUSP10 affected the dephosphorylation of the TAK1, and regulated the degree of pyroptosis by mediating the TAK1/JNK/p38 pathway. In conclusion, our study indicates that DUSP10 is a novel mediator of SAP and can inhibit pyroptosis via the dephosphorylation of TAK1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.